文献速递哮喘

肥胖对新发成人哮喘患者12年长期预后的影响

Long-term prognosis of new adult-onset asthma in obese patients.
PubMed 文献 · Eur Respir J · 2021-04-01

该研究基于Seinäjoki成人哮喘研究,将203例新诊断成人哮喘患者按诊断时BMI分为三组并随访12年。结果显示,诊断时肥胖者86%在12年后仍肥胖,且口服糖皮质激素使用更频繁、剂量更高,呼吸相关住院率也更高。肥胖可预测口服激素使用和住院风险。

要点

  • 诊断时肥胖的成人哮喘患者12年后多数仍肥胖,应优先考虑减重。
  • 肥胖组口服糖皮质激素使用率及剂量均高于正常体重组。
  • 肥胖组呼吸相关住院率显著更高,肥胖可预测不良预后。

核心结论

  • 诊断时肥胖的新发成人哮喘患者长期多维持肥胖状态,且12年内口服激素使用及呼吸相关住院风险更高。

研究设计与样本

  • 基于Seinäjoki成人哮喘研究,纳入203例新诊断成人哮喘患者,按诊断时BMI(<25、25-29.9、≥30 kg·m-2)分三组随访12年。

主要发现

  • 诊断时肥胖者86%在12年后仍肥胖,各BMI组间体重增加无差异。
  • 肥胖组报告口服激素疗程更频繁(46.9% vs 23.1%,p=0.028)。
  • 肥胖组口服激素配药更频繁(81.6% vs 56.9%,p=0.014)且剂量更高(中位1350 mg vs 600 mg泼尼松龙,p=0.010)。
  • 肥胖组呼吸相关住院率更高(38.8% vs 16.9%,p=0.033)。
  • 多因素logistic回归显示肥胖预测口服激素使用和住院。

临床怎么用

  • 对新诊断成人哮喘的肥胖患者,应将减重作为优先治疗目标以预防不良预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity has been associated with poor outcomes of asthma in cross-sectional studies, but long-term effect of obesity on asthma remains unknown. AIMS: To study the effects of obesity, found at the time of diagnosis of adult-onset asthma, on 12-year prognosis by focusing on oral corticosteroid (OCS) use and respiratory-related hospital admissions. METHODS: Patients diagnosed with adult-onset asthma (n=203) were divided into three categories based on diagnostic body mass index (BMI) (<25 kg·m-2, 25-29.9 kg·m-2, ≥30 kg·m-2) and followed for 12 years as part of the Seinäjoki Adult Asthma Study. Self-reported and dispensed OCS were assessed for the 12-year period. Data on hospital admissions were analysed based on medical records. RESULTS: 12 years after diagnosis, 86% of the patients who were obese (BMI ≥30 kg·m-2) at diagnosis remained obese. During the follow-up, no difference was found in weight gain between the BMI categories. During the 12-year follow-up, patients obese at diagnosis reported more frequent use of OCS courses (46.9% versus 23.1%, p=0.028), were dispensed OCS more often (81.6% versus 56.9%, p=0.014) and at higher doses (median 1350 (interquartile range 280-3180) mg versus 600 (0-1650) mg prednisolone, p=0.010) compared to normal-weight patients. Furthermore, patients who were obese had more often one or more respiratory-related hospitalisations compared to normal-weight patients (38.8% versus 16.9%, p=0.033). In multivariate logistic regression analyses, obesity predicted OCS use and hospital admissions. CONCLUSIONS: In adult-onset asthma, patients obese at diagnosis mostly remained obese at long-term and had more exacerbations and respiratory-related hospital admissions compared to normal-weight patients during 12-year follow-up. Weight loss should be a priority in their treatment to prevent this outcome.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Ilmarinen P, Pardo A, Tuomisto LE, et al. Long-term prognosis of new adult-onset asthma in obese patients. Eur Respir J. 2021. PMID: 33033149. doi:10.1183/13993003.01209-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。